137262 research outputs found
Sort by
Targeting PTSD with ultramicronized palmitoylethanolamide: Results from a randomized trial integrating pharmacotherapy and cognitive behavioral therapy
No full textBackground: Post-Traumatic Stress Disorder (PTSD) is a debilitating psychiatric condition with limited pharmacological options and high rates of partial response to cognitive behavioral therapy (CBT), the current gold standard. Recent evidence implicates the endocannabinoid system and neuroinflammation in PTSD pathophysiology. Palmitoylethanolamide (PEA), an endogenous lipid mediator with anti-inflammatory and neuroprotective properties, has emerged as a promising candidate for mitigating PTSD symptoms, in particular when administered in its ultramicronized formulations (PEA-um). Methods: In a randomized, placebo-controlled clinical trial, 60 patients diagnosed with PTSD according to DSM-5 criteria were assigned to one of four treatment arms: PEA-um, PEA-um + CBT, placebo and placebo + CBT. Participants were assessed at five-time points over 18 months using the PTSD Checklist for DSM-5 (PCL-5) and the Hamilton Anxiety Rating Scale (HAM-A). Statistical analysis was conducted using Generalized Linear Mixed Models (GLMMs), controlling for age and gender. Results: All active treatments resulted in a significant reduction of PTSD and anxiety symptoms, with the PEA-um + CBT group showing the most pronounced and sustained improvements. At 18 months, mean PCL-5 and HAM-A scores in this group decreased from 67,3 ± 1,77 to 20,0 ± 2,12 and 49,6 ± 1,21 to 19,4 ± 1,81, respectively. Significant time × group interaction effects were observed (p < 0,0001), and no serious adverse events were reported. Discussion: The findings support the efficacy of PEA-um, particularly in combination with CBT, in alleviating PTSD symptoms. The results align with preclinical data highlighting PEA's role in modulating neuroinflammatory pathways and emotional regulation. Conclusion: PEA-um, especially when combined with CBT, represents a promising and well-tolerated adjunctive treatment for PTSD, warranting further validation in larger clinical trials
DOPO IL VOTO REFERENDARIO: SCENARI E PROSPETTIVE
No full textDibattito sulle prospettive legate all’esito del referendum costituzionale sulla revisione del titolo IV della costituzion
Global Trials, Local Relevance: A Scientific and Regulatory Framework for Regional Enrollment in Cancer Drug Development
No full textPurpose: Global oncology trials face increasing scrutiny over regional enrollment imbalances, as regulatory agencies such as the US Food and Drug Administration, European Medicines Agency, and Pharmaceuticals and Medical Devices Agency demand data reflective of population diversity. This push is grounded in evidence that genetic polymorphisms (eg, UGT1A1*28, CYP2D6), human leukocyte antigen-related toxicities, and biomarker prevalence (eg, epidermal growth factor receptor mutations in approximately 15% of Western v approximately 50% of Asian patients with lung cancer) can significantly influence treatment outcomes. Methods: We reviewed scientific literature, regulatory case studies, and methodological innovations addressing regional heterogeneity in oncology trials. Particular focus was given to statistical tools such as adaptive randomization for real-time enrollment balancing, Bayesian hierarchical models for data borrowing across regions, and Multi-Regional Clinical Trial designs for structured consistency assessments. Control arm variability because of regional differences in standard of care and drug access was also examined. Results: Recent regulatory setbacks, especially involving Asia-centric trials, underscore the consequences of insufficient regional planning. Emerging statistical approaches, including adaptive and Bayesian methods, show promise in managing heterogeneity while preserving trial integrity. Persistent challenges include disparities in trial infrastructure, molecular subtype distributions, and comorbidity patterns. Broader regional inclusion and integration of real-world evidence are increasingly critical to overcoming these limitations. Conclusion: Regional enrollment should be viewed not as a regulatory formality, but as a scientific and ethical priority. The future of global oncology trials hinges on proactive regional planning, innovative methodology, and cross-sector collaboration. Aligning global efficiency with local relevance can enhance scientific robustness, support regulatory alignment, and expand equitable access to novel cancer therapies worldwide
La disciplina in materia di armi
No full textUna circolare interpretativa del Ministero dell’Interno illustra le novità introdotte dal d.lgs. n.104 del 2018 in materia di armi.
È stato pubblicato sulla Gazzetta Ufficiale n.209 dell’8 settembre 2018 il decreto legislativo 10 agosto 2018 n.104, recante “Attuazione della
direttiva Ue 2017/853 del Parlamento europeo e del Consiglio, del 17 maggio 2017, che modifica la direttiva 91/477/Cee del Consiglio,
relativa al controllo dell’acquisizione e della detenzione di armi”. D.lgs. 10 agosto 2018 n.10
Sharp estimates for the Laplacian torsional rigidity with negative Robin boundary conditions
No full textMotivated by pioneering works of Bandle and Wagner, given a bounded Lipschitz domain Ω⊂Rd with d≥3, we consider the Robin-Laplacian torsional rigidity τα(Ω) with negative boundary parameter α and we show that sharp inequalities for τα(Ω) hold if |α| is small enough. In particular, we prove that, if |α| is smaller than the first non-trivial Steklov-Laplacian eigenvalue, then the ball maximises τα(Ω) among all convex domains under perimeter or volume this solves an open problem raised by Bandle and Wagner. We also prove the result in the planar case among simply connected sets and under perimeter constraint
Colorimetric aptasensor for exosome detection in breast cancer liquid biopsy
No full textExosomes are nanoscale extracellular vesicles (EVs) that carry molecular signatures reflective of their cells of origin, making them attractive biomarkers for liquid biopsy applications. In this study, we present a rapid and highly specific colorimetric aptasensor for the detection of Gremlin-1 (GREM1)-expressing exosomes in serum. The sensing strategy relies on the disaggregation of gold nanoparticle (AuNP) clusters, initially formed by NaCl-induced aggregation, upon selective binding of the target. AuNPs were functionalized with a thiolated Ex.50.T aptamer specifically recognizing exosomal GREM1, and the binding event triggers a measurable spectral shift in the plasmonic profile. A detection limit below 106 exosomes/mL was achieved using serial dilutions of purified exosomes isolated from breast cancer serum samples, demonstrating the method’s sensitivity and robustness under controlled conditions. Applied to 100 clinical serum samples, the assay demonstrated excellent diagnostic performance, with 84% sensitivity and 90% specificity—values comparable to those of mammography—without requiring extensive sample processing. Comparative analysis with commercial ELISA and Ex.50.T aptamer-based ELONA confirmed the superior discriminatory power of the method proposed here. Transmission electron microscopy further corroborated the mechanism by revealing exosomes physically disrupting AuNP aggregates. These results highlight the diagnostic potential of exosome-focused sensing strategies and establish this aptamer-based colorimetric platform as a promising candidate for non-invasive screening of breast cancer through liquid biopsy
